SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

FDC informs about updates

23 Aug 2024 Evaluate
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, FDC has informed that U.S. Food and Drug Administration (FDA) had conducted an inspection at Company’s manufacturing facility located at Baddi, Himachal Pradesh which is dedicated for manufacturing Cephalosporin Oral dosage forms. The said audit has been successfully completed by the US FDA with ‘No observations’ (Zero 483’s).

The above information is a part of company’s filings submitted to BSE.

FDC Share Price

359.60 0.95 (0.26%)
20-Apr-2026 14:37 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.90
Dr. Reddys Lab 1235.10
Cipla 1232.95
Zydus Lifesciences 936.50
Lupin 2327.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×